Twitter icon
Facebook icon
Instagram icon
YouTube icon
Click to go to mail form
Click to get search form

Hartzler Demands Action on Made-In-China Pharmaceuticals

May 8, 2020
Press Release

WASHINGTON, D.C. – Congresswoman Vicky Hartzler (MO-04) and Congressman John Garamendi (CA-03) sent a letter to President Trump urging action to bring pharmaceutical manufacturing and its supply chain back to the United States.

As the White House discusses the tools at its disposal to keep Americans safe from the threats posed by China, Hartzler and Garamendi, who are co-sponsors of H.R. 4710, the Pharmaceutical Independence Long-Term Readiness Act, issued the letter voicing support for strong measures to be taken to safeguard domestic and national security interests from China. The COVID-19 pandemic has exposed a serious vulnerability for both national security and public health and there is bipartisan support in Congress for ending our nation’s reliance on China for pharmaceuticals and their ingredients.

“This pandemic has made one thing certain: it’s time for America and our allies to stand up to China and safeguard these vulnerabilities. Right now, China has the ability to attack the United States without firing a single shot. Their control over the pharmaceutical supply chain and the lack of government oversight and accountability, as seen during this global pandemic, gives the Chinese Communist Party the ability to directly poison our servicemembers and manipulate the supply of medications they need while on duty. While this is truly a grave and concerning national security concern, these vulnerabilities extend to all Americans as well. Beijing has continuously proven that it cannot be a trusted, well-behaved actor in the world. We must make it a top priority to protect American citizens from China’s deceitful and manipulative behavior. I thank Rep. Garamendi for joining efforts with me and exemplifying the bipartisan support these actions have in Congress,” Hartzler said.
 
“The Chinese government is the principal supplier of generic drugs, which account for approximately 90 percent of all pharmaceuticals prescribed. Treating COVID-19 quickly and effectively will require a robust domestic pharmaceutical manufacturing sector, which the United States currently lacks. That’s why Congresswoman Hartzler and I have sent bipartisan legislation to the President detailing our plan to bolster America’s domestic drug manufacturing and end China’s chokehold on the global pharmaceutical supply chain. The current pandemic proves our nation can no longer remain so overly reliant on medical supplies from mainland China. Our letter to the President shows strong bipartisan determination in Congress to strengthen domestic drug manufacturing to meet the incredible needs brought on by the coronavirus pandemic,” Garamendi said.
 
An electronic copy of the letter can be found here.